Hepion (HEPA) grants chair 1.35M stock options at $0.08
Rhea-AI Filing Summary
Hepion Pharmaceuticals, Inc. (HEPA) reported that Executive Chairman Vincent S. LoPriore received a grant of stock options on 2026-08-19. The award covers 1,345,500 options to acquire common stock at an exercise price of $0.08 per share, expiring on 2036-08-19. According to the footnote, 336,375 options vest upon grant and the remaining options vest in equal monthly installments over six months from the grant date. Following this grant, LoPriore holds 1,345,500 stock options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
LoPriore Vincent S
Role
Executive Chairman
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options F1 | 1,345,500 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options — 1,345,500 shares (Direct)
Footnotes (1)
- F1. 336,375 options vest upon grant and the remaining amount vests in equal amounts monthly over 6 months from date of grant.
Key Figures
Stock options granted: 1,345,500 options
Exercise price: $0.08 per share
Immediate vesting portion: 336,375 options
+3 more
6 metrics
Stock options granted
1,345,500 options
Grant to Executive Chairman Vincent S. LoPriore on 2026-08-19
Exercise price
$0.08 per share
Conversion or exercise price for granted stock options
Immediate vesting portion
336,375 options
Options that vest upon grant per footnote F1
Expiration date
2036-08-19
Expiration date of the granted stock options
Underlying shares
1,345,500 shares
Common stock underlying the granted options
Options held after transaction
1,345,500 options
Total derivative holdings reported following the grant
Key Terms
Stock Options, exercise price, expiration date, vesting
4 terms
Stock Options financial
"The security title is listed as "Stock Options" for this grant"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise price financial
"The filing shows a conversion or exercise price of 0.0800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"An expiration date of 2036-08-19 is provided for the options"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"Footnote F1 explains that some options vest upon grant and others monthly"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What insider transaction did HEPA disclose for Vincent S. LoPriore?
Hepion Pharmaceuticals (HEPA) disclosed that Executive Chairman Vincent S. LoPriore received a grant of 1,345,500 stock options on 2026-08-19 as a derivative security award, rather than buying or selling shares on the open market.
What is the exercise price and term of the new HEPA stock options?
The granted stock options have an exercise price of $0.08 per share and an expiration date of 2036-08-19, giving Vincent S. LoPriore the right to acquire Hepion common stock at that price until that date.
How do the new HEPA options granted to LoPriore vest?
The filing states that 336,375 options vest upon grant, and the remaining options vest in equal amounts monthly over six months from the 2026-08-19 grant date.
How many HEPA options does Vincent S. LoPriore hold after this transaction?
After the reported grant, Vincent S. LoPriore holds 1,345,500 stock options directly, as shown in the post-transaction holdings figure in the Form 4.
Was the HEPA option grant to LoPriore made under a Rule 10b5-1 trading plan?
No. The filing’s Rule 10b5-1 checkbox is not affirmed (false), and there is no footnote indicating the grant was made pursuant to a Rule 10b5-1 or other pre-arranged trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
